Clinical trials: Cholangiocarcinoma Cancer
Biliary Tract Cancer, Cholangiocarcinoma
Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer
The NEOBIL study aims to investigate the feasibility, safety and efficacy of neoadjuvant Bintrafusp alfa in patients with resectable biliary tract cancer.
- Trial name
- NEOBIL (NCT04727541)
- Testing
- Bintrafusp alfa
- Where
- 2 sites in Germany
- Volunteers
- 3 people
- Sponsor
- AIO-Studien-gGmbH
Bile Duct Cancer, Pancreas Cancer
Radio Frequency Ablation in the Management of Pancreatico-biliary Disorders: A Multicenter Registry.
Bile duct cancer and pancreatic cancer are cancers that cannot be surgically removed. As the cancer grows, it blocks the drainage of the bile ducts that carry digestive juices from the gallbladder and pancreas to the small…
- Trial name
- NCT04937322
- Testing
- Interventional Endoscopy procedures
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Methodist Health System
Advanced Solid Tumor, Metastatic Solid Tumor
A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors
This study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of WM-S1-030 in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Colorectal Cancer, Lung Cancer
- Trial name
- NCT04801095
- Testing
- WM-S1-030
- Where
- 6 sites in Australia, South Korea
- Volunteers
- 100 people
- Sponsor
- Wellmarker Bio
Hepatocholangiocarcinoma, Fibrolamellar Carcinoma
A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers
The aim of this French multicenter retrospective study is to describ rare primary hepatic cancers clinical, histological and radiological features, to obtain a biological tumor and blood collection, and to evaluate the efficacy…
- Conditions
- Hepatocholangiocarcinoma, Fibrolamellar Carcinoma, Hepatic Epithelioid Hemangioendothelioma, Hepatoblastoma
- Trial name
- FFCD-2205 (NCT06541652)
- Where
- 40 sites in France
- Volunteers
- 150 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Cholangiocarcinoma of the Extrahepatic Bile Duct, Gallbladder Cancer
Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
The purpose of this study is to evaluate the feasibility, efficacy and safety of target therapy according to genomic and proteomic profiling combined with GEMOX in advanced or recurrent extrahepatic cholangiocarcinoma and…
- Trial name
- NCT02836847
- Testing
- biological test, GEMOX, Cetuximab
- Where
- China
- Volunteers
- 152 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Obstruction of Biliary Tree, Cholangiocarcinoma
Comparison Between Unilateral Versus Bilateral Stenting for Malignant Hilar Biliary Obstruction to Use a LCD Stent
Internal biliary drainage is an useful method for a control of jaundice and cholangitis to patients who had a malignant hilar obstruction due to hepatocellular carcinoma, cholangiocarcinoma, gall bladder cancer or metastatic…
- Conditions
- Obstruction of Biliary Tree, Cholangiocarcinoma, Hepatocellular Carcinoma, Malignant Lymphadenopathy
- Trial name
- NCT01875549
- Testing
- stent insertion, Endoscopic retrograde cholangiopancreatoscopy(ERCP)
- Sponsor
- Kwang Hyuck Lee
Cholangiocarcinoma, Bile Duct Obstruction
Endoscopic Biliary RFA of Malignant Bile Duct Obstruction
Endoscopic radiofrequency ablation (RFA) is a new palliation therapy for malignant bile duct obstruction. It delivers a high amount of thermal energy to target tissue and may prolong the duration of stent patency.
- Trial name
- NCT02582541
- Testing
- SEMS alone, SEMS plus radiofrequency ablation
- Where
- China
- Volunteers
- 100 people
- Sponsor
- The Second Hospital of Nanjing Medical University
Durvalumab, Intrahepatic Cholangiocarcinoma
Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk
This study is a randomized controlled study to evaluate the efficacy and safety of Durvalumab combined with GemCis for neoadjuvant treatment of high recurrence risk ICC
- Conditions
- Durvalumab, Intrahepatic Cholangiocarcinoma, Gemcis
- Trial name
- NCT05672537
- Testing
- Durvalumab, Surgery, Gemcitabine
- Where
- China
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Cholangiocarcinoma
Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)
The purpose of this study is evaluate the efficacy of pemigatinib in subjects with advanced/metastatic or surgically unresectable cholangiocarcinoma with FGFR2 translocation who have failed at least 1 previous treatment.
- Trial name
- NCT02924376
- Testing
- Pemigatinib
- Where
- 120 sites in United States, Belgium and 10 more
- Volunteers
- 147 people
- Sponsor
- Incyte Corporation
Cholangiocarcinoma, Bile Duct Neoplasm
Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers
Background: Cholangiocarcinoma (CCA) is an aggressive cancer of the bile ducts. People with CCA have few treatment options and poor survival. Researchers want to see if a new drug can stop or slow CCA growth.
- Conditions
- Cholangiocarcinoma, Bile Duct Neoplasm, Biliary Tract Malignancy
- Trial name
- NCT04645160
- Testing
- Tivozanib
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Cholangiocarcinoma
International Registry on Cholangiocarcinoma Treatment
Cholangiocarcinoma is a rare and very aggressive neoplasm that arises from the biliary epithelium, constitutes approximately 2% of all reported cancer, and accounts for about 3% of all gastrointestinal malignancies.
- Trial name
- CHOLANGIO (NCT01920503)
- Testing
- Doxorubicin
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- International Group of Endovascular Oncology
Bile Duct Stricture, Bile Duct Cancer
PTFE Stents for Treatment of Malignant Biliary Strictures
In this randomized trial two two self-expanding metal stents (SEMS) for treatment of malignant biliary strictures are investigated.
- Conditions
- Bile Duct Stricture, Bile Duct Cancer, Pancreas Cancer
- Trial name
- NCT03763214
- Testing
- Stenting with PTFE-coated stent (HILZO)
- Where
- Germany
- Volunteers
- 64 people
- Sponsor
- Johannes Vermehren
Cholangiocarcinoma
Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma
This research study is studying Dasatinib as a possible treatment for cancer of bile ducts.
- Trial name
- NCT02428855
- Testing
- Dasatinib
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Massachusetts General Hospital
Metastatic Solid Tumors, Stage 4 Cancer
The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.
This is a sequential, dose-escalation, non-randomized, prospective, early feasibility trial. The goal of this clinical trial is to gather information on the safety and the recommended dose of the Sarah Nanotechnology System.
- Trial name
- NCT07224464
- Testing
- The Sarah Nanotechnology System - intended to deliver thermal energy to malignant cells for the purpose of thermal destruction of these cells in patients with advanced metastatic solid tumors.
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- New Phase Ltd.
Solid Tumor, Adult, Clinical Stage IV Gastric Cancer AJCC v8
Intravital Microscopy in Human Solid Tumors
This study will investigate the tumor-associated vasculature of patients with solid tumors. The investigators will use a technology known as intravital microscopy (IVM) in order to visualize in real-time the vessels associated…
- Conditions
- Solid Tumor, Adult, Clinical Stage IV Gastric Cancer AJCC v8, Malignant Solid Neoplasm, Metastatic Colorectal Carcinoma
- Trial name
- NCT03823144
- Testing
- Diagnostic Microscopy, Fluorescein Sodium Injection
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Mayo Clinic
Advanced Solid Tumor, BRAF V600 Mutation
A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors
This is a Phase I, Open-Label, Multicenter, Dose Escalation and Expansion Study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-cancer activity of ABM-1310 in patients with BRAF V600-Mutant advanced…
- Trial name
- NCT05501912
- Testing
- ABM-1310
- Where
- 10 sites in China
- Volunteers
- 20 people
- Sponsor
- ABM Therapeutics Shanghai Company Limited
Hepatocellular Carcinoma, Primary Liver Cancer
Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms
The purpose of this study is to test the efficacy of a collaborative care intervention to manage cancer-related symptoms and improve health related quality of life in patients diagnosed with hepatobiliary carcinoma.
- Conditions
- Hepatocellular Carcinoma, Primary Liver Cancer, Bile Duct Cancer, Pancreatic Cancer
- Trial name
- CaSSY (NCT01640522)
- Testing
- Collaborative Care, Enhanced usual Care
- Where
- United States
- Volunteers
- 261 people
- Sponsor
- University of Pittsburgh
Advanced Biliary Tract Cancer, Intrahepatic Cholangiocarcinoma
Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer
This study is an open-label, phase II study of irinotecan liposome injection in patients with advanced biliary tract cancer. The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics of irinotecan…
- Conditions
- Advanced Biliary Tract Cancer, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma
- Trial name
- NCT05009953
- Testing
- Irinotecan Liposome Injection, SG001, Fluorouracil
- Where
- China
- Volunteers
- 17 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Intrahepatic Cholangiocarcinoma
Establishment of Scoring Model for Early and Differential Diagnosis of Intrahepatic Cholangiocarcinoma
The purpose of this study is to develop and validate a radiological nomogram including radiological characteristics, clinical risk factors, and medical history.
- Trial name
- NCT05327907
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Qilu Hospital of Shandong University
Hepato Cellular Carcinoma, Intrahepatic Bile Duct Carcinoma
Inter-Individual Tumor Heterogeneity on 3D-MRE for Predicting Response to Conversion Therapy in Liver Cancer
How to predict which patients with initially unresectable liver cancer are more likely to respond to conversion therapy remains an important unresolved problem in guiding treatment strategy and surgical timing.
- Conditions
- Hepato Cellular Carcinoma, Intrahepatic Bile Duct Carcinoma, Metastatic Hepatocellular Carcinoma
- Trial name
- NCT07716345
- Testing
- Three-Dimensional Magnetic Resonance Elastography
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.